Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
AO-176 by Arch Oncology for Refractory Multiple Myeloma: Likelihood of Approval
AO-176 is under clinical development by Arch Oncology and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData,...